drugset / Trial / NCT00258687

Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

NCT00258687 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to learn if a vaccine made from the patient's own tumor cells, then genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), will delay or stop the growth of the tumor. It will also look at the vaccine's effects on the immune system and the side effects of giving a vaccine made from a subject's own cancer cells.

Timeline

Start
2005-01
Primary completion
2006-07
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GVAX Vaccine — Subcutaneous